

NOTIFICATION AND FORM FOR ADVANCE VOTING

The form shall be received by Vicore Pharma Holding AB (publ) no later than on 29 April 2026

The shareholder set out below hereby notifies of its participation and exercises its voting right for all of the shareholder's shares in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the "**Company**") at the Annual General Meeting on 6 May 2026. The voting right is exercised in accordance with the below marked voting options.

Shareholder	Personal identity number/registration number
-------------	--

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):

I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this vote in advance on behalf of the shareholder and that the contents of the vote in advance correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions for advance voting:

- Complete the information above.
- Select the preferred voting options below.
- Print, sign and send the original form by post to Vicore Pharma Holding AB (publ), Attn: Nina Carlén, Kornhamnstorg 53, SE-111 27 Stockholm, Sweden, or via e-mail to nina.carlen@vicorepharma.com.
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- A power of attorney shall be enclosed if the shareholder submits its votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form.
- A shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the Company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

A shareholder who has voted in advance may also attend the meeting venue, provided that notification has been made in accordance with the instructions stated in the notice convening the meeting. If a shareholder has voted in advance as well as has notified its participation to attend the meeting at the meeting venue, in person or by proxy, the vote cast in advance is still valid to the extent that the shareholder does not participate in a voting procedure at the meeting or otherwise withdraws the vote in advance. If the shareholder chooses to participate in a voting at the meeting, the vote cast will replace the previously submitted vote in advance with regard to the relevant item on the agenda. Please note that the advance vote does not constitute a notice of participation to attend the meeting venue in person or by proxy.

The advance voting form, together with any enclosed authorization documentation, shall be received by the Company no later than on 29 April 2026. An advance vote can be withdrawn up to and including 29 April 2026 by contacting the Company by e-mail to nina.carlen@vicorepharma.com. Thereafter, advance votes may only be revoked by the shareholder attending the meeting in person or through a proxy.

For further information and complete proposals for the items on the agenda, kindly refer to the notice convening the Annual General Meeting at the Company's website, www.vicorepharma.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Vicore Pharma Holding AB (publ) on 6 May 2026

The options below comprise the proposals submitted to the Annual General Meeting which are included in the notice convening the Annual General Meeting.

2.	Election of chairman of the meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
5.	Determination of whether the meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
6.	Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
8.a	Resolution regarding adoption of income statement and balance sheet and the consolidated income statement and consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8.b	Resolution regarding allocation of the Company's profit or loss in accordance with the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c	Resolution regarding discharge from liability of the Board of Directors and the CEO
8.c.i	Hans Schikan, chairman of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.ii	Jacob Gunterberg, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.iii	Elisabeth Björk, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.iv	Michael Buschle, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.v	Heidi Hunter, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.vi	Ann J. Barbier, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.vii	Yasir Al-Wakeel, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c.viii	Ahmed Mousa, CEO Yes <input type="checkbox"/> No <input type="checkbox"/>
9.	Determination of the number of board members and auditors
9.a	Number of board members Yes <input type="checkbox"/> No <input type="checkbox"/>
9.b	Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
10.	Determination of fees to the Board of Directors and the auditors
10.a	Fees to the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
10.b	Fees to the auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
11.	Election of members of the Board of Directors
11.a	Hans Schikan, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11.b	Jacob Gunterberg, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>

11.c	Elisabeth Björk, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11.d	Heidi Hunter, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11.e	Ann J. Barbier, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11.f	Yasir Al-Wakeel, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11.g	Peter Guenter, new election Yes <input type="checkbox"/> No <input type="checkbox"/>
12.	Election of the chairman of the Board of Directors
12.a	Hans Schikan, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
13.	Election of auditors and, where applicable, deputy auditors
13.a	Ernst & Young Aktiebolag, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
14.	Presentation of the Board of Directors' remuneration report for approval Yes <input type="checkbox"/> No <input type="checkbox"/>
15.	Resolution regarding authorization for the Board of Directors to issue new shares, warrants and/or convertibles Yes <input type="checkbox"/> No <input type="checkbox"/>
16.	Resolution regarding adoption of an equity-based program for the members of the Board of Directors
16.a	Resolution regarding adoption of an equity-based program Yes <input type="checkbox"/> No <input type="checkbox"/>
16.b	Resolution regarding issue and approval of transfer of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
16.c	Resolution regarding equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
17.	Resolution regarding adoption of a co-worker long-term incentive program
17.a	Resolution regarding adoption of a co-worker long-term incentive program Yes <input type="checkbox"/> No <input type="checkbox"/>
17.b	Resolution regarding issue and approval of transfer of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
17.c	Resolution regarding equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>